DK2343380T3 - Immunoglobulin variabel region kassetteudskiftning - Google Patents
Immunoglobulin variabel region kassetteudskiftning Download PDFInfo
- Publication number
- DK2343380T3 DK2343380T3 DK10014128.2T DK10014128T DK2343380T3 DK 2343380 T3 DK2343380 T3 DK 2343380T3 DK 10014128 T DK10014128 T DK 10014128T DK 2343380 T3 DK2343380 T3 DK 2343380T3
- Authority
- DK
- Denmark
- Prior art keywords
- variable region
- immunoglobulin variable
- cartridge replacement
- region cartridge
- replacement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62858104P | 2004-11-16 | 2004-11-16 | |
EP05851809.3A EP1824987B1 (en) | 2004-11-16 | 2005-11-16 | Immunoglobulin variable region cassette exchange |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2343380T3 true DK2343380T3 (da) | 2019-09-09 |
Family
ID=36407771
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10014128.2T DK2343380T3 (da) | 2004-11-16 | 2005-11-16 | Immunoglobulin variabel region kassetteudskiftning |
DK19169135.1T DK3540062T3 (da) | 2004-11-16 | 2005-11-16 | Immunoglobulin-variabel region kassetteudskiftning |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19169135.1T DK3540062T3 (da) | 2004-11-16 | 2005-11-16 | Immunoglobulin-variabel region kassetteudskiftning |
Country Status (10)
Country | Link |
---|---|
US (2) | US20060134098A1 (da) |
EP (3) | EP3540062B1 (da) |
JP (1) | JP2008520586A (da) |
AU (1) | AU2005306502B2 (da) |
CA (1) | CA2587158C (da) |
DK (2) | DK2343380T3 (da) |
ES (3) | ES2744149T3 (da) |
PL (2) | PL3540062T3 (da) |
PT (2) | PT2343380T (da) |
WO (1) | WO2006055778A2 (da) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
BRPI0506629A (pt) * | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
WO2006055778A2 (en) | 2004-11-16 | 2006-05-26 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
BRPI0618160A2 (pt) * | 2005-05-26 | 2011-08-16 | Univ Colorado | inibição da via alternativa complemento para tratamento de danos cerebrais traumáticos, danos na medula espinhal e condições relacionadas |
WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
US20080171038A1 (en) * | 2006-11-08 | 2008-07-17 | Kalobios Pharmaceuticals, Inc. | Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist |
EA200900709A1 (ru) | 2006-11-21 | 2009-12-30 | Калобиос Фармасьютикалс, Инк. | Способы лечения хронических воспалительных заболеваний с использованием антагониста gm-csf |
US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
CA2678451A1 (en) * | 2007-02-20 | 2008-08-28 | Robert A. Horlick | Somatic hypermutation systems |
PT3199180T (pt) * | 2007-03-08 | 2022-04-01 | Univ Monash | Anticorpos epha3 para o tratamento de tumores sólidos |
JP5872757B2 (ja) * | 2007-03-14 | 2016-03-01 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ヒト化抗b因子抗体 |
EP2176297A1 (en) * | 2007-07-17 | 2010-04-21 | Irm Llc | Antagonist antibodies of protease activated receptor-1 (par1) |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
NZ586357A (en) | 2007-11-30 | 2012-10-26 | Kalobios Pharmaceuticals Inc | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
US9873957B2 (en) | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
ES2528963T3 (es) | 2008-04-24 | 2015-02-13 | Dyax Corp. | Bibliotecas de paquetes genéticos que comprenden nuevos diseños de CDR1, CDR2, y CDR3 de HC y nuevos diseños de CDR1, CDR2, y CDR3 de LC |
DK2280732T3 (da) * | 2008-04-28 | 2019-01-28 | Humanigen Inc | Antistoffer mod granulocyt-makrofag-koloni-stimulerende faktor |
US20100272736A1 (en) | 2009-02-04 | 2010-10-28 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
US9079942B2 (en) | 2009-02-09 | 2015-07-14 | Epitomics, Inc. | CDR-anchored amplification method |
WO2010093814A1 (en) | 2009-02-11 | 2010-08-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a gm-csf antagonist |
WO2010102244A1 (en) | 2009-03-06 | 2010-09-10 | Kalobios Pharmaceuticals, Inc. | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
US8921281B2 (en) * | 2009-05-20 | 2014-12-30 | Novimmune S.A. | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
EP2453906A4 (en) | 2009-07-02 | 2014-01-15 | Musc Found For Res Dev | METHOD FOR STIMULATING THE LIVER REGENERATION |
US8293483B2 (en) | 2009-09-11 | 2012-10-23 | Epitomics, Inc. | Method for identifying lineage-related antibodies |
JP2013508292A (ja) | 2009-10-14 | 2013-03-07 | カロバイオス ファーマシューティカルズ インコーポレイティッド | EphA3に対する抗体 |
AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
JP5686817B2 (ja) | 2009-12-22 | 2015-03-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 配列依存性の凝集 |
BR112012020790B1 (pt) | 2010-02-18 | 2021-09-28 | The Regents Of The University Of California | Anticorpo isolado anti-integrina alfavbeta8 e composição farmacêutica |
CA2794851A1 (en) * | 2010-04-02 | 2011-10-06 | Kalobios Pharmaceuticals, Inc. | Generation of antibodies to an epitope of interest |
JP2014511378A (ja) | 2011-02-11 | 2014-05-15 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Pcsk9アンタゴニスト |
US9880160B2 (en) | 2011-03-15 | 2018-01-30 | X-Body, Inc. | Antibody screening methods |
WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
WO2012170607A2 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Use of pcsk9 antagonists |
WO2013052582A2 (en) * | 2011-10-05 | 2013-04-11 | Kalobios Pharmaceuticals, Inc. | Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid |
BR112014010008A2 (pt) | 2011-10-26 | 2018-09-04 | Novartis Ag | anticorpos monoclonais, seus usos e ácidos nucleicos |
WO2013177035A2 (en) | 2012-05-24 | 2013-11-28 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor b antibody |
WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
AR096601A1 (es) | 2013-06-21 | 2016-01-20 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
KR102311761B1 (ko) | 2013-12-09 | 2021-10-13 | 알라코스 인크. | 항-Siglec-8 항체 및 그의 사용 방법 |
CA2939931A1 (en) | 2014-02-28 | 2015-09-03 | Christopher Robert Bebbington | Methods and compositions for treating siglec-8 associated diseases |
NZ723520A (en) * | 2014-06-17 | 2018-06-29 | Academia Sinica | Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CA2987797A1 (en) | 2015-06-17 | 2016-12-22 | Christopher Robert Bebbington | Methods and compositions for treating fibrotic diseases |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
WO2017093947A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
WO2018053032A1 (en) | 2016-09-13 | 2018-03-22 | Humanigen, Inc. | Epha3 antibodies for the treatment of pulmonary fibrosis |
EP3532496A1 (en) | 2016-10-28 | 2019-09-04 | Banyan Biomarkers, Inc. | Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
SG11201910193VA (en) | 2017-05-05 | 2019-11-28 | Allakos Inc | Methods and compositions for treating allergic ocular diseases |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
CN110662762A (zh) | 2017-05-24 | 2020-01-07 | 诺华股份有限公司 | 抗体细胞因子移植蛋白和用于治疗癌症的方法 |
WO2018215938A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
CN111757744A (zh) | 2017-10-02 | 2020-10-09 | 人源股份有限公司 | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |
US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
US20220064301A1 (en) | 2018-12-26 | 2022-03-03 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
TW202317612A (zh) | 2021-03-01 | 2023-05-01 | 美商艾希利歐發展股份有限公司 | 用於治療癌症的ctla4及pd1/pdl1抗體之組合 |
WO2022187272A1 (en) | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3742105A (en) | 1970-05-05 | 1973-06-26 | S Kuroda | Method for producing a seamless tubing |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
ATE102631T1 (de) * | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6969586B1 (en) * | 1989-05-16 | 2005-11-29 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
HU219537B (hu) | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JP3720353B2 (ja) * | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
CA2229043C (en) * | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
WO1999029888A1 (en) * | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
ES2263626T3 (es) | 2000-06-05 | 2006-12-16 | Corixa Corporation | Peptidos lider para potenciar la secrecion de proteina recombinante a partir de una celula hospedante. |
WO2002000005A1 (en) | 2000-06-21 | 2002-01-03 | Alexion Pharmaceuticals, Inc. | Libraries displaying human antibody fragments with hybrid complementarity determining regions |
IL166244A0 (en) * | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
US20030219839A1 (en) * | 2001-09-20 | 2003-11-27 | Katherine Bowdish | Anti-PDGF antibodies and methods for producing engineered antibodies |
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
CA2485732A1 (en) * | 2002-05-20 | 2003-12-04 | Abmaxis, Inc. | Generation and selection of protein library in silico |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
WO2004072266A2 (en) * | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
EP2990053A1 (en) * | 2004-01-20 | 2016-03-02 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
WO2006055178A2 (en) | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
WO2006055778A2 (en) | 2004-11-16 | 2006-05-26 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
US20090175847A1 (en) * | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
-
2005
- 2005-11-16 WO PCT/US2005/041825 patent/WO2006055778A2/en active Application Filing
- 2005-11-16 PT PT10014128T patent/PT2343380T/pt unknown
- 2005-11-16 PL PL19169135T patent/PL3540062T3/pl unknown
- 2005-11-16 JP JP2007541495A patent/JP2008520586A/ja active Pending
- 2005-11-16 AU AU2005306502A patent/AU2005306502B2/en not_active Ceased
- 2005-11-16 EP EP19169135.1A patent/EP3540062B1/en active Active
- 2005-11-16 ES ES10014128T patent/ES2744149T3/es active Active
- 2005-11-16 US US11/282,107 patent/US20060134098A1/en not_active Abandoned
- 2005-11-16 ES ES05851809T patent/ES2429541T3/es active Active
- 2005-11-16 EP EP05851809.3A patent/EP1824987B1/en not_active Revoked
- 2005-11-16 EP EP10014128.2A patent/EP2343380B1/en active Active
- 2005-11-16 CA CA2587158A patent/CA2587158C/en active Active
- 2005-11-16 DK DK10014128.2T patent/DK2343380T3/da active
- 2005-11-16 DK DK19169135.1T patent/DK3540062T3/da active
- 2005-11-16 PT PT191691351T patent/PT3540062T/pt unknown
- 2005-11-16 PL PL10014128T patent/PL2343380T3/pl unknown
- 2005-11-16 ES ES19169135T patent/ES2881353T3/es active Active
-
2015
- 2015-12-14 US US14/968,709 patent/US10919983B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2587158C (en) | 2016-01-12 |
PT3540062T (pt) | 2021-07-06 |
EP2343380B1 (en) | 2019-06-12 |
EP2343380A1 (en) | 2011-07-13 |
CA2587158A1 (en) | 2006-05-26 |
PL3540062T3 (pl) | 2021-12-27 |
ES2429541T3 (es) | 2013-11-15 |
JP2008520586A (ja) | 2008-06-19 |
EP3540062A1 (en) | 2019-09-18 |
US20060134098A1 (en) | 2006-06-22 |
US10919983B2 (en) | 2021-02-16 |
DK3540062T3 (da) | 2021-06-28 |
WO2006055778A3 (en) | 2006-11-23 |
EP3540062B1 (en) | 2021-05-12 |
PT2343380T (pt) | 2019-09-18 |
EP1824987A2 (en) | 2007-08-29 |
EP1824987B1 (en) | 2013-08-21 |
AU2005306502B2 (en) | 2012-11-15 |
ES2744149T3 (es) | 2020-02-21 |
US20160102152A1 (en) | 2016-04-14 |
PL2343380T3 (pl) | 2020-03-31 |
ES2881353T3 (es) | 2021-11-29 |
EP1824987A4 (en) | 2008-03-19 |
AU2005306502A1 (en) | 2006-05-26 |
WO2006055778A2 (en) | 2006-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2343380T3 (da) | Immunoglobulin variabel region kassetteudskiftning | |
DE602005027428D1 (de) | Toner | |
DE602005026205D1 (de) | Rasiersystem | |
DE602004019389D1 (de) | Toner | |
ATE446263T1 (de) | Mehrkomponenten-kartusche | |
DE112005000643T5 (de) | Filtervorrichtung | |
DE602006009742D1 (de) | Austauschfilter | |
DE112006002166A5 (de) | Kartusche | |
DE602004030654D1 (de) | Farbbandkassette | |
ATE534013T1 (de) | Patrone | |
DE602005019940D1 (de) | Linseneinrichtung | |
DE602005000846D1 (de) | Plattenkassette | |
DK1812475T3 (da) | Immunglobulinfraktioner | |
DE602005019938D1 (de) | Linseneinrichtung | |
FI20041019A0 (fi) | Virtaussäädin | |
DE602005022812D1 (de) | Gleitschienen | |
DE602004018608D1 (de) | Filtervorrichtung | |
AT7367U3 (de) | Filterkartusche | |
SE0400022D0 (sv) | New compounds | |
DE502005005025D1 (de) | Buchbeschlag | |
UA10920S (uk) | Картридж бритви | |
UA12032S (uk) | Тонер картридж | |
UA12601S (uk) | Картридж бритви | |
SE0400254D0 (sv) | New compounds | |
IS8562A (is) | Ónæmisglóbúlín |